Universal Beteiligungs und Servicegesellschaft mbH Invests $5.51 Million in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 130,853 shares of the biopharmaceutical company's stock, valued at approximately $5,505,000. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of Ultragenyx Pharmaceutical at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of RARE. Smartleaf Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $35,000. Human Investing LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the 4th quarter valued at about $42,000. Van ECK Associates Corp grew its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 273 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $82,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Stock Down 3.3%

RARE traded down $1.16 during trading on Friday, reaching $33.87. 1,631,431 shares of the stock traded hands, compared to its average volume of 838,842. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The stock has a market capitalization of $3.20 billion, a PE ratio of -5.34 and a beta of 0.34. The stock's 50-day moving average is $35.61 and its 200 day moving average is $40.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same quarter in the prior year, the business earned ($2.03) EPS. The firm's revenue for the quarter was up 28.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on RARE shares. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Morgan Stanley raised their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Canaccord Genuity Group upped their price target on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Finally, Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Monday, March 17th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $88.77.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $607,881.90. Following the transaction, the insider now directly owns 107,766 shares of the company's stock, valued at approximately $4,536,948.60. This trade represents a 11.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emil D. Kakkis sold 73,434 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the completion of the transaction, the chief executive officer now owns 641,731 shares in the company, valued at $27,016,875.10. The trade was a 10.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 97,415 shares of company stock valued at $4,094,958 over the last 90 days. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.